In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation
Applied Biochemistry and Biotechnology · 2024
DOI: 10.1007/s12010-024-04958-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, 2024. Verfasst von Mona H Ibraheim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Physics Department, Faculty of Science, Zagazig University, P.O.44519, Zagazig, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, ErbB Receptors, Molecular Docking Simulation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Vascular endothelial growth factor is an angiogenic that promotes the development and metastasis of tumors (VEGF). The epidermal growth factor receptor, or EGFR, controls the division, growth, and death of cells via several signaling pathways. It has been found that most of the tyrosine kinase EGFR/VEGFR-2 inhibited by drugs that the FDA has approved are so far. The main objective of the present study was to identify an efficacious and selective dual inhibitor of VEGFR-2/EGFR for the treatment of cancer. Out of the 400 ligands tested against the kinases, 12 compounds demonstrated the best docking scores through molecular docking for the two kinases. Of these, only compound SCHEMBL2435814 inhibited the kinases with the highest score values when compared to a reference, vandetanib, as a dual inhibitor of EGFR/VEGFR-2 kinases through interaction with the identified active sites pocket. Following drug-likeness score toxicity and pharmacokinetic testing, the two compounds, SCHEMBL2435814 and vandetanib, were analyzed to determine how the two kinases interacted with each other. The results of calculations of π-cation interactions, hydrogen bonds, and hydrophobic interactions demonstrated a strong interaction between the two kinases and SCHEMBL2435814. Eventually, molecular dynamic modeling was used to assess the stability of complexes. This demonstrated many characteristics, including RMSF, RMSD, SASA, RG, and H-bond analysis, which demonstrated that SCHEMBL2435814 with the two kinases was more stable than vandetanib over a 100ns simulation period. By suppressing EGFR/VEGFR-2, chemical SCHEMBL2435814 may be able to postpone the signaling pathway of proteins that are essential to the advancement of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Physics Department, Faculty of Science, Zagazig University, P.O.44519, Zagazig, Egypt.
- Physics Department, Faculty of Science, Zagazig University, P.O.44519, Zagazig, Egypt. imaher@science.zu.edu.eg.
- Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
Zitieren
APA
Ibraheim, M. H., Maher, I., & Khater, I. (2024). In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-024-04958-8
Vancouver
Ibraheim MH, Maher I, Khater I. In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation. Applied Biochemistry and Biotechnology. 2024. doi:10.1007/s12010-024-04958-8
BibTeX
@article{Ibraheim2024,
author = {Ibraheim, Mona H and Maher, Ibrahim and Khater, Ibrahim},
title = {In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation},
journal = {Applied Biochemistry and Biotechnology},
year = {2024},
doi = {10.1007/s12010-024-04958-8}
}
EUVIMED